≥98% HPLC PURITY

Tirzepatide

5mg / 10 VIALS

MINDTEK · RESEARCH USE ONLY

RESEARCH USE ONLY COA VERIFIED SOLUTION PHASE

Tirzepatide

GLP-1 / GIP Receptor Dual Agonist

39-amino-acid synthetic peptide with a C20 fatty-diacid moiety. Dual agonist at the GIP and GLP-1 receptors, modulating glucose-dependent insulin secretion, gastric emptying, and satiety signalling.

MW: 4813.45 Da CAS: 2023788-19-2 Per Vial: 5mg Kit: 10 Vials

SELECT QUANTITY

1 Vial $120Order

3 Vials Save 9%$109 eaOrder

5 Vials Save 18%$99 eaOrder

10 Vials Best Value$89 eaOrder

Mechanism of Action

Tirzepatide is engineered from the native GIP sequence to co-agonise the GIP and GLP-1 receptors. Receptor engagement potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces energy intake in research models. Its GIP-biased profile distinguishes it from single-incretin GLP-1 agonists.

⚡

GLP-1 Receptor Agonism

Glucose-dependent insulinotropic signalling and appetite suppression via central and peripheral GLP-1 receptors.

🔬

GIP Receptor Agonism

Complementary incretin-axis engagement enhancing insulin response and lipid handling.

🧬

Glucoregulatory Effect

Glucagon suppression and delayed gastric emptying documented across independent research groups.

Research Evidence

DATA = directly reported in cited study · INFERENCE = derived · SPECULATION = hypothesis

Coskun T et al. (2018) Mol Metab 18:3-14DATA

Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, improved glucose control and reduced body weight vs. selective GLP-1 agonism in preclinical models (DATA).

Frias JP et al. (2021) N Engl J Med 385(6) SURPASS-2DATA

Tirzepatide 5-15 mg reduced HbA1c and body weight dose-dependently vs. semaglutide 1 mg over 40 weeks (DATA).

Jastreboff AM et al. (2022) N Engl J Med 387(3) SURMOUNT-1DATA

Up to 20.9% mean body-weight reduction at 72 weeks vs. placebo in adults without diabetes (DATA).

Certificate of Analysis

Every Mindtek batch is independently tested before release. We were among the first peptide suppliers in Southeast Asia to implement mandatory third-party HPLC verification — a standard, not an exception.

HPLC Purity≥98.0%

Bacterial Endotoxins≤5 EU/mg

Water Content (Karl Fischer)≤8.0%

Peptide Content≥80%

StandardUSP/EP

Request CoA for This Batch →

Research Protocol Reference

For laboratory research use only — not for human or veterinary use.

💧

Reconstitution

Add sterile bacteriostatic water (0.9% benzyl alcohol) slowly against the vial wall. Gently swirl — do not vortex. Allow 5 min for complete dissolution.

🧊

Storage

Store solution-phase at -20°C. Post-reconstitution: maintain at 2–8°C, use within 28 days. Protect from light. Avoid repeated freeze-thaw cycles.

📐

Administration

SubQ or IM administration in standard research protocols. Insulin syringe recommended for precise dosing. Refer to published literature for compound-specific protocols.

Frequently Asked Questions

What is Tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide (dual GIP/GLP-1 receptor agonist) engineered from the native GIP sequence. Research applications: metabolic, glucoregulatory, and energy-balance studies. Research use only.

How is Mindtek Tirzepatide produced?

Synthesised via solid-phase peptide synthesis (SPPS). Each batch: HPLC purity verification (≥99.3%), mass spectrometry identity, endotoxin testing prior to release.

Storage requirements?

Store solution-phase Tirzepatide at -20°C. Post-reconstitution with sterile BAC water: 2–8°C, use within 28 days. Avoid repeated freeze-thaw cycles.

Ready to Order Tirzepatide?

Mindtek ships solution-phase, independently verified research compounds to qualified researchers globally. First in Southeast Asia.

Place an Order Research Hub